METiS Pharmaceuticals
剂泰科技
METiS Pharmaceuticals is an AI-driven pharmaceutical company specializing in drug formulation and delivery, founded in August 2019 in Boston and incubated by XtalPi . The company was established by a team of MIT scientists and US National Academy of Engineering members, with co-founder & CEO Caida Lai, a former Novartis-MIT Center researcher and McKinsey consultant, alongside co-founder & CRDO Hongmin Chen, a serial pharma entrepreneur, and co-founder & COO Wenshou Wang, a small-molecule synthesis and AI expert .
METiS positions itself as the world's first company to apply artificial intelligence to pharmaceutical formulation development, combining high-throughput experimental platforms with AI algorithms and quantum chemistry simulations to optimize drug delivery systems . Its core technical capabilities include nanoscale formulations, microspheres, and oral controlled-release designs, with particular strength in mRNA sequence design and LNP delivery systems that reportedly achieve expression efficiency exceeding industry standards by over tenfold .
The company has attracted significant venture backing, with FreeS Fund leading its angel round in late 2019 and subsequently participating in four funding rounds, while Source Code Capital made its first AI pharma investment in METiS and continued to increase its stake across multiple rounds . Other investors include Sequoia China, 5Y Capital, Lightspeed China, and Monolith . METiS completed two consecutive funding rounds totaling $150 million in 2022 , followed by a $100 million Series C in 2024 , and ultimately listed on the Hong Kong Stock Exchange in May 2026 under ticker 7666.HK, raising over HK$2.1 billion in what became the largest Hong Kong healthcare IPO of that year .
AI-generated — may contain errors, please verify.
Coverage
AI for Pharmaceutical Chemical Synthesis: Can Today's AI Match a Chemist with 10 Years of Experience?
AI for Science is becoming one of the hottest directions in the primary market.
Models, Tokens, and Organizations in the Post-Scaling Law Era | 5Y Quarterly
We can only see a short distance ahead, but we can already see that there is much to be done.
3 IPOs Leading the Pack, 11 Companies Land New Funding | FreeS Family Funding News Vol.26
Looking forward to working alongside more outstanding founders.
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
Has the Inflection Point for AI for Science Arrived?
Where will the next Nobel Prize emerge?
Congratulations to "Yifei Technology" on its listing on the Hong Kong Stock Exchange — FreeS Fund's third Hong Kong IPO of 2026.
"All Spark" — the "spark source" from *Transformers*
On the Eve of IPO, a Conversation with METiS Pharmaceuticals' Caida Lai: From Formulas on a Whiteboard to "The SpaceX of Pharma"
The story behind the investment.
5Y News | Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange listing!
METiS Pharmaceuticals, the world's first publicly listed AI-driven drug delivery company, goes public, ushering in a new era for biopharmaceuticals.
Congratulations to METiS Pharmaceuticals on its Hong Kong Stock Exchange IPO — FreeS Fund invested in four consecutive early rounds.
From Whiteboard Equations to the "SpaceX" of Pharma
Heart Capital Congratulates METiS Pharmaceuticals on Successful Listing on the Main Board of the Hong Kong Stock Exchange | Heart Star PORTFOLIO
The world's first publicly listed AI drug delivery company.
Metis Pharmaceuticals lists today, marking Monolith's first HKEX IPO
The scientist who pitched in a KFC just went public today.
Code Moment | Congratulations to METiS Pharmaceuticals on Its HKEX Listing, the World's First AI Drug Delivery Stock
Source Code Capital participated in METiS Pharmaceuticals' angel round in 2020 and continued to increase its stake in subsequent rounds.
AI for Science Investment and Entrepreneurship: Where Are the Opportunities in the Next Decade?
"That failed data is valuable."
Five Sources Capital Promotes Its First Post-90s Partner
How Do VCs Grow New Capabilities?
From Two Rounds in Six Months to a $400M Series D: 10 Companies Announce New Funding | FreeS Family Funding News Vol.24
Looking forward to working alongside more outstanding founders.
Changing Every Today for Tomorrow | 5Y News Monthly
The big news from last month.
MaHui | Multiple MaHui Member Companies Named to MIT Technology Review's Annual "50 Smartest Companies"
Unitree, Moonshot AI, WITMEM, Keenon Robotics, METiS Pharmaceuticals, and DeepWise made the list.
The SpaceX of Pharma: Caida Lai's Nanorocket
Only those with fire in their eyes can build rockets.
Compile Uncertainty into Answers | 5Y News Monthly
The big news from last month.
MaHui Spotlight | MaHui Member METiS Pharmaceuticals Closes RMB 400 Million Series D to Help Build Beijing's Biotech "New Engine"
April: Curiosity and New Paths | 5Y News Monthly
The big news from last month.
Miracles Come from Perseverance | 5Y News Monthly
The big news from last month.
MaHui Members Make Zero2IPO's 2024 VENTURE50 List
December: No End to Progress | 5Y News Monthly
The big news from last month.
AI for Science: Standing at the Turning Point of a Research Paradigm | FreeS Fund Report
What is AI for Science, and why now?
MaHui Spotlight | Multiple MaHui Members Named to Wealth's 40 Under 40 China Business Elite and Other Lists
Young leaders are driving a revolutionary transformation of productivity.
New Listings and New Funding: 10 Developments in the Height of Summer | FreeS Family Funding News Vol.19
Looking forward to working alongside more outstanding founders.
Confidence Is Tomorrow's Trailblazer | 5Y News Monthly
The major events that happened last month.
MaKe | MaHui Member METiS Pharmaceuticals Closes $100 Million Series C, Leading the "AI + Drug Delivery" Track
5Y News | 5Y Capital Portfolio Company METiS Pharmaceuticals Closes $100 Million Series C Round
Focused on "AI-powered drug delivery."
Congratulations to XtalPi on its Successful IPO: How FreeS Fund's Research-Driven Approach Learns from Investing
AI + Robotics Creates First 18C Listing — Congratulations to XtalPi
MaKe | Multiple MaHui Members Named to 2023 China Healthcare Industry Investment and Financing Glory List
Spend a Summer on a VC Journey of "Seeking Truth" and "Taking Things Seriously" | FreeS Fund's 2024 Internship Program Is Now Open
Welcome aboard — a great workplace is one with a bunch of amazing colleagues.
The beginning of a miracle often lies within the thing itself | 5Y News Monthly
The big news from last month.
Success is rarely replicable; what matters is finding your own path | 5Y View x Bota Bio x METiS Pharmaceuticals
Cross-disciplinary methodology for entrepreneurship.
MaHui Moment | Multiple MaHui Members Named to Hurun China Under 35s Entrepreneurs to Watch 2023
Several MaHui members were named to the *2023 Hurun China Under 35s* list.
Entrepreneurship is a climb where the journey itself is the reward.
The journey is the reward.
Monolith's Xi Cao and His Eleven Musketeers
Starting a business is like climbing a mountain — the meaning lies in the climb itself.
MONOLITH砺思资本｜Riding with Great Tech Companies
Think to know, and temper through action.
June, the World's Childhood | 5Y News Monthly
The big news from last month.
Li Xiang x Li Feng: Why Did ChatGPT Emerge Today? What Happens Next? | Li Feng Column
Is there still a chance to build a Chinese OpenAI?
Hongshan Healthcare Investing: 17 Years From the Sidelines to Center Stage
Going earlier and deeper has become a defining feature of Hongshan's healthcare investments.
The 6 Questions Young People Care About Most: We Asked 17 Founders | FreeS Fund Youth Festival & Graduation Season Special
Passion and conviction are what carry you through the darkness.
Hongshan Seed Deploys Another $480 Million, Early-Stage Investing Is About to Get Even More Crowded
What Should Seed Investing Look Like in a New Cycle?
MaHui | Multiple MaHui Members Named to ChinaVenture's "Sharp 100" List
Finding True Non-Consensus: Time as a Moat | 5Y Capital Partner Meeting Recap
Focus only on things that are absolutely meaningful.
How to Invest in Biotech in 2023? | FreeS Research
Data-driven, cross-disciplinary, bearing fruit — the most certain direction amid uncertainty
FreeS Fund's Seventh Anniversary: Working Together to Go Further
Welcome to the team.
[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave
Going live tomorrow at 10 a.m. sharp.
The unthinkable is precisely what can be thought. | 5Y News Monthly
The big news from last month.
MaHui | Multiple MaHui Members Win Awards at HICOOL 2022 Global Entrepreneurship Competition
MaHui Entrepreneurs | AI4S Industrialization Roundtable: With So Many Application Scenarios, "AI Tools" Will Deliver Greater Value
What Are the Opportunities for Biotech Over the Next Decade? | A FreeS Fund Conversation
Breaking Through the "Great Stagnation" in Technology: Biotechnology Is a Critical Breakthrough
August: Reasons to Stay Confident | 5Y News Monthly
The big news from last month.
MaHui Founder | Post-90s Entrepreneur Zhang Junbin: Building Transformative Products, Pursuing Zero-to-One Value
July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
What Happens When the Hottest Tech Sectors Collide? | FreeS Fund Chip Series
How do cross-disciplinary ventures that push the boundaries of imagination achieve steady, grounded commercialization?
From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
MaHui | Nearly 40 MaHui Members Named to 36Kr's X·36Under36 S-Class Young Entrepreneurs List
New Tracks, Interdisciplinary Fields, Down-Market Expansion, Data Infrastructure... Four Companies Raise Nearly 1.2 Billion RMB in Funding | FreeS Family Funding News · Vol 10
Looking forward to working alongside more outstanding founders.
Interdisciplinary Frontier Entrepreneurship: How Chips Are Reshaping Every Industry | May 15 Livestream Registration
See you on May 15!
The world begins anew each day in a light that is forever fresh. | 5Y News Monthly
The major events from last month.
Source Code Capital | "Xijie Fried Skewers" Announces 75 Million Yuan Series A+ Funding Round, Source Code Capital Co-Led Series A Round
A highly standardized, normalized digital supply chain system.
5Y News | METiS Pharmaceuticals Closes Two Consecutive Rounds Raising $150 Million Total
Become an industry innovation leader.
Code Engraved | METiS Pharmaceuticals Announces Two Consecutive Rounds totaling $150 Million
The most advanced pipeline programs are expected to begin pivotal clinical trials in 2023.
Farewell to a Year of Inflection Points: Will 2022 Be Better? | Li Feng's New Year Outlook
Where the heart leads, steady steps take you far.
"The Tech + Biotech" Crossover: A New Investment Consensus on Convergent Innovation
Professional, systematic, and patient for the long haul.
New Opportunities Amid the Great Transformation in Drug R&D | FreeS Fund Dialogue Session 2 Now Open for Registration
Breakthroughs and Acceleration in New Drug R&D
Source Code Capital closes fifth RMB fund, raising over 7 billion yuan to back tech innovation and SMEs
Invest early, invest small, invest in tech
Source Code Capital's Xingshi Wang and Yungang Huang Named MVIP Young Investors of the Year and Best Digital Healthcare Investor
MVIP of the Year, Best Investor in Digital Healthcare.
5Y Capital's Xu Tian Jing: Why We're Bullish on Digital Pharmaceutical R&D | 5Y Talk
The ITBT track has a promising future ahead.
FreeS Fund 2021 Outlook ② | Three Trends in Biomedical Innovation
The Biopharma Industry Enters the "Three Fast" Era
Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biomedical VC Summit Transcript
Why We're Bullish on AI Drug Discovery
FreeS Fund received eight recognitions from institutions including *Fortune* (Chinese edition), 36Kr, and the Fund of Funds Alliance.
Do what's right, not what's easy.
Source Code Capital portfolio company YiCan announced the completion of a multi-million-dollar Pre-A funding round, with existing investor Source Code Capital continuing to increase its stake.
The company serves nearly 1,000 clients, with 70% being post-Series A companies or those generating annual revenue exceeding RMB 20 million.
Our Past 100 Days: Sailing Against the Wind, Growing Toward the Sun
Venture Capital's Pandemic Fight: A Chronicle
Guofeng Content E-Commerce Platform *Wanwudezhi* Closes Tens of Millions of Dollars in Series B Funding, Led by Source Code Capital
It hit 2 billion yuan in revenue within a year of launch.
World's First Smart Mopping Robot 'Cloud Whale' Announces Close to 100 Million Yuan Series B Funding Led by Source Code Capital and ByteDance
The World's First Smart Mopping Robot
![[Live Tomorrow] In Conversation with Bluepha | Synthetic Biology: From Groping in the Dark to Riding the Wave](/_next/image?url=https%3A%2F%2Fkkcktdhgzddmdjdjoenc.supabase.co%2Fstorage%2Fv1%2Fobject%2Fpublic%2Fmedia%2Fimages%2F45f83c6a-7c35-4040-ba2d-210c7948ac95%2Fd7061a92cbcc.jpg&w=384&q=75)
